ネオスチグミンメチル硫酸塩注射剤市場：用量別、適応症別、流通経路別、最終用途別、地域別

ネオスチグミンメチル硫酸塩注射剤市場は、2025年には1億7,150万米ドルと推定され、2032年には2億3,340万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は4.5%で成長すると予測されています。

ネオスチグミンメチル硫酸塩注射剤はコリンエステラーゼ阻害剤であり、重症筋無力症の治療の補助薬として、また手術室や集中治療室での非脱分極性神経筋遮断剤の毒性治療における解毒薬として使用されます。本薬は、神経筋接合部で神経伝達物質アセチルコリンを分解するアセチルコリンエステラーゼ酵素を阻害することにより作用します。この酵素を阻害することにより、ネオスチグミンメチル硫酸塩はアセチルコリンの作用を延長し、神経筋伝達と筋力を増加させる。四肢、体幹、咽喉、眼などの骨格筋の筋力低下などの重症筋無力症の症状管理に役立ちます。過量投与や過敏な患者では、神経筋接合部における刺激が増大し、吐き気、唾液の増加、筋肉のけいれんなどの副作用を引き起こす可能性があります。

市場力学：

高齢者人口の増加は、予測期間中もネオスチグミンメチル硫酸塩注射剤の世界市場の成長を促進すると思われます。高齢者は重症筋無力症のような神経疾患にかかりやすく、ネオスチグミンメチル硫酸塩注射剤による治療が頻繁に必要となります。医療費の増加も、予測期間中、世界のネオスチグミンメチル硫酸塩注射剤市場の成長を促進し続けると思われます。動物医療の成長は、予測期間中、世界のネオスチグミンメチル硫酸塩注射剤市場に新たな機会を創出すると思われます。ネオスチグミンメチル硫酸塩注射剤は、獣医学、特に動物のいくつかの神経筋疾患の治療にも使用されています。獣医業界におけるネオスチグミンメチル硫酸塩注射剤の使用と入手可能性を高めることで、新たな商業的展望が開けるかもしれないです。

知識と診断の欠如が、予測期間中の世界のネオスチグミンメチル硫酸塩注射剤市場の成長を妨げると予想されます。

本調査の主な特徴

• 本レポートでは、世界のネオスチグミンメチル硫酸塩注射剤市場を詳細に分析し、2024年を基準年とした予測期間2025-2032年の市場規模および年間平均成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案のマトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 世界のネオスチグミンメチル硫酸塩注射剤市場における主要な企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
• 本レポートから得られる洞察により、マーケティング担当者や各企業の経営陣は、将来の製品上市、タイプアップ、市場拡大、マーケティング戦術に関して、十分な情報に基づいた意思決定を行うことができます。
• 世界のネオスチグミンメチル硫酸塩注射剤市場レポートは、投資家、サプライヤー、製品メーカー、販売業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者を対象としています。
• 利害関係者は、世界のネオスチグミンメチル硫酸塩注射剤市場の分析に使用される様々な戦略マトリックスを通じて、意思決定が容易になります。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
• 重症筋無力症や術後腸閉塞など、ネオスチグミンを必要とする疾患の罹患率が上昇している
• 知識と診断の欠如
• 獣医学の成長
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ

第4章 世界のネオスチグミンメチル硫酸塩注射剤市場- コロナウイルス（COVID-19）パンデミックの影響

• COVID-19疫学
• 供給側と需要側の分析
• 経済への影響

第5章 ネオスチグミンメチル硫酸塩注射剤市場、用量別、2020年～2032年

• 1 mg/mL
• 0.5mg/mL

第6章 ネオスチグミンメチル硫酸塩注射剤市場、適応症別、2020年～2032年

• 重症筋無力症
• 神経筋遮断の解除

第7章 世界のネオスチグミンメチル硫酸塩注射剤市場、流通経路別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 世界のネオスチグミンメチル硫酸塩注射剤市場、最終用途別、2020-2032年

• 病院
• 専門クリニック
• 外来手術センター

第9章 ネオスチグミンメチル硫酸塩注射剤市場、地域別、2020年～2032年

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • フランス
  • スペイン
  • ロシア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • ASEAN
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
  • その他ラテンアメリカ
• 中東・アフリカ
  • GCC
  • イスラエル
  • その他中東
  • 北アフリカ
  • 中央アフリカ
  • 南アフリカ

第10章 競合情勢

• Baxter International Inc.
• Pfizer Inc.
• Fresenius Kabi AG
• Boehringer Ingelheim GmbH
• Mylan N.V.
• Novartis International AG
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd.
• Sandoz（a division of Novartis）
• Accord Healthcare Inc.
• Lannett Company, Inc.
• Mallinckrodt Pharmaceuticals
• Lupin Limited

第11章 セクション

• 調査手法
• 出版社について

Neostigmine Methylsulfate Injection Market is estimated to be valued at USD 171.5 Mn in 2025 and is expected to reach USD 233.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.5% from 2025 to 2032.

Neostigmine methylsulfate injection is a cholinesterase inhibitor that is used as an adjunct in the treatment of myasthenia gravis and as an antidote in the treatment of non-depolarizing neuromuscular blocking agent toxicity in the operating room or intensive care unit setting. It acts by inhibiting the acetylcholinesterase enzyme, which normally breaks down the neurotransmitter acetylcholine at the neuromuscular junction. By inhibiting this enzyme, neostigmine methylsulfate prolongs the actions of acetylcholine, increasing neuromuscular transmission and muscle strength. It helps in the management of myasthenia gravis symptoms such as weakness of the skeletal muscles of the extremities, trunk, throat, and eyes. In overdose or sensitive patients, it can cause increased stimulation at the neuromuscular junction and produce side effects such as nausea, increased saliva, and muscle cramps.

Market Dynamics:

The increasing geriatric population will continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The elderly are more susceptible to neurological conditions like myasthenia gravis, which frequently needs to be treated with injections of neostigmine methylsulfate. Rising medical expenditures will also continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The growth of veterinary medicine will create new opportunities for the global neostigmine methylsulfate injection market over the forecast period. Injections of neostigmine methylsulfate are also employed in veterinary medicine, particularly for the treatment of a few neuromuscular diseases in animals. It may open up new commercial prospects to increase the use and availability of neostigmine methylsulfate injections in the veterinary industry.

Lack of knowledge and diagnosis is expected to hamper the growth of the global neostigmine methylsulfate injection market over the forecast period.

Key Features of the Study:

• This report provides an in-depth analysis of the global neostigmine methylsulfate injection market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neostigmine methylsulfate injection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Baxter International Inc., Pfizer Inc., Fresenius Kabi AG, Boehringer Ingelheim GmbH, Mylan N.V., Novartis International AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Sandoz (a division of Novartis), Accord Healthcare Inc., Lannett Company, Inc., Mallinckrodt Pharmaceuticals, and Lupin Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global neostigmine methylsulfate injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neostigmine methylsulfate injection market

Detailed Segmentation:

• Global Neostigmine Methylsulfate Injection Market, By Dosage:
  • 1 mg/mL
  • 0.5 mg/mL
• Global Neostigmine Methylsulfate Injection Market, By Indications:
  • Myasthenia Gravis
  • Reversal of Neuromuscular Blockade
• Global Neostigmine Methylsulfate Injection Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Neostigmine Methylsulfate Injection Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
• Global Neostigmine Methylsulfate Injection Market, By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profile:
  • Baxter International Inc.
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Boehringer Ingelheim GmbH
  • Mylan N.V.
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC
  • GlaxoSmithKline plc
  • Sun Pharmaceutical Industries Ltd.
  • Sandoz (a division of Novartis)
  • Accord Healthcare Inc.
  • Lannett Company, Inc.
  • Mallinckrodt Pharmaceuticals
  • Lupin Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Neostigmine Methylsulfate Injection Market, By Dosage
  • Neostigmine Methylsulfate Injection Market, By Indication
  • Neostigmine Methylsulfate Injection Market, By Distribution Channel
  • Neostigmine Methylsulfate Injection Market, By End User
  • Neostigmine Methylsulfate Injection Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Rising prevalence of diseases like myasthenia gravis and postoperative ileus requiring neostigmine
  • Restraints
• Lack of knowledge and diagnosis
  • Opportunities
• Growth of veterinary medicine
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Neostigmine Methylsulfate Injection Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Neostigmine Methylsulfate Injection Market, By Dosage, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• 1 mg/mL
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• 0.5 mg/mL
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

6. Global Neostigmine Methylsulfate Injection Market, By Indication, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Myasthenia Gravis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Reversal of Neuromuscular Blockade
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

7. Global Neostigmine Methylsulfate Injection Market, By Distribution Channel, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

8. Global Neostigmine Methylsulfate Injection Market, By End User, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)

9. Global Neostigmine Methylsulfate Injection Market, By Region, 2020-2032, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region 2021 - 2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Fresenius Kabi AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals PLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sandoz (a division of Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Accord Healthcare Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lannett Company, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Mallinckrodt Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

11. Section

• Research Methodology
• About us